Clinical Trial Update: Regorafenib in Relapsed Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for regorafenib in relapsed glioblastoma (glioblastoma multiforme) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Istituto Oncologico Veneto IRCCS | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED